Nikko Asset Management Americas Inc. Acquires 880,370 Shares of Compugen Ltd. (CGEN)

Nikko Asset Management Americas Inc. increased its holdings in shares of Compugen Ltd. (NASDAQ:CGEN) by 14,153.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 886,590 shares of the biotechnology company’s stock after acquiring an additional 880,370 shares during the quarter. Nikko Asset Management Americas Inc. owned about 1.73% of Compugen worth $3,670,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in CGEN. Morgan Stanley grew its stake in Compugen by 2.8% during the third quarter. Morgan Stanley now owns 998,173 shares of the biotechnology company’s stock worth $3,843,000 after buying an additional 27,240 shares in the last quarter. Matrix Asset Advisors Inc. NY grew its stake in Compugen by 20.8% during the fourth quarter. Matrix Asset Advisors Inc. NY now owns 104,500 shares of the biotechnology company’s stock worth $227,000 after buying an additional 18,000 shares in the last quarter. Jane Street Group LLC acquired a new stake in Compugen during the third quarter worth about $128,000. Renaissance Technologies LLC grew its stake in Compugen by 8.2% during the third quarter. Renaissance Technologies LLC now owns 265,100 shares of the biotechnology company’s stock worth $1,021,000 after buying an additional 20,200 shares in the last quarter. Finally, Taylor Frigon Capital Management LLC grew its stake in Compugen by 17.2% during the fourth quarter. Taylor Frigon Capital Management LLC now owns 690,262 shares of the biotechnology company’s stock worth $1,498,000 after buying an additional 101,212 shares in the last quarter. 27.86% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:CGEN traded up $0.08 during mid-day trading on Friday, hitting $3.34. 44,400 shares of the company’s stock were exchanged, compared to its average volume of 152,158. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.11 and a quick ratio of 4.66. Compugen Ltd. has a fifty-two week low of $2.00 and a fifty-two week high of $4.31. The company has a market cap of $171.57 million, a PE ratio of -8.15 and a beta of 2.43.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, May 20th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities research analysts expect that Compugen Ltd. will post -0.57 EPS for the current year.

A number of research firms have recently weighed in on CGEN. Oppenheimer set a $9.00 price target on shares of Compugen and gave the company a “buy” rating in a research note on Tuesday, February 26th. Zacks Investment Research upgraded shares of Compugen from a “hold” rating to a “strong-buy” rating and set a $4.00 target price on the stock in a research report on Friday, March 1st.

TRADEMARK VIOLATION NOTICE: This article was first reported by Sundance Herald and is owned by of Sundance Herald. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://sundanceherald.com/2019/05/24/nikko-asset-management-americas-inc-has-3-67-million-holdings-in-compugen-ltd-cgen.html.

Compugen Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

See Also: SEC Filing

Institutional Ownership by Quarter for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply